A shipment of doses of the Sputnik V (Gam-Covid-Vac) vaccine against the coronavirus is seen after arriving at Ezeiza International Airport, in Buenos Aires, Argentina on Jan 28. Reuters/File
Scientists gave Russia’s Sputnik V vaccine the green light on Tuesday saying it was almost 92 per cent effective in fighting Covid-19 based on peer-reviewed late-stage trial results published in
Experts said the Phase 3 trial results meant the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow’s decision to roll out the vaccine before final data had been released.
The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September.
Sputnik V Covid vaccine 91.6% effective in Phase-III trial: Peer-reviewed data
(Photo: Reuters)
. Updated: 02 Feb 2021, 06:18 PM IST Agencies
Russia s Gamaleya Institute publishes peer-reviewed results of Sputnik V Covid-19 vaccine in the Lancet medical journal
The vaccine was found equally effective in people aged above 60, shows trial data
Share Via
Read Full Story
Russia s Sputnik V vaccine is 91.6 percent effective against symptomatic Covid-19 in Phase-III trial, according to peer-reviewed results published in The Lancet medical journal on Tuesday.
The preliminary findings show that the two-dose Sputnik V has shown high efficacy and was well tolerated for participants over 18 in final-stage clinical trials, said co-lead author Inna Dolzhikova of Russia s Gamaleya National Research Centre for Epidemiology and Microbiology.
Russia s Sputnik V vaccine 92% effective in fighting COVID-19 Reuters 2/02/2021
By Polina Ivanova
MOSCOW (Reuters) - Scientists gave Russia s Sputnik V vaccine the green light on Tuesday saying it was almost 92% effective in fighting COVID-19 based on peer-reviewed late-stage trial results published in The Lancet international medical journal.
Experts said the Phase III trial results meant the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow s decision to roll out the vaccine before final data had been released.
The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September.
Study reports preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine trial 2-Feb-2021 2:15 PM EST, by Lancet
Interim analysis from phase 3 trial of nearly 20,000 participants suggests efficacy of two-dose regimen of the adenovirus-based vaccine is 91.6% against symptomatic COVID-19 - trial reports 16 COVID-19 cases in the vaccine group (0.1% [16/14,964) and 62 cases (1.3% [62/4,902]) in the placebo group.
No serious adverse events were deemed to be associated with vaccination, and most reported adverse events were mild, including flu-like symptoms, pain at injection site and weakness or low energy.
Sub-analysis of 2,000 adults older than 60 years suggests the vaccine is similarly effective and well tolerated in this group.